Preview

Архивъ внутренней медицины

Расширенный поиск

ПРИМЕНЕНИЕ НИКОРАНДИЛА ПРИ СЕРДЕЧНО-СОСУДИСТЫХ ЗАБОЛЕВАНИЯХ И ОПТИМИЗАЦИЯ СХЕМ ЕГО НАЗНАЧЕНИЯ

https://doi.org/10.20514/2226-6704-2012-0-1-46-52

Полный текст:

Аннотация

Никорандил – антиангинальный препарат с уникальным двойным фармакологическим действием: он является активатором АТФ-зависимых калиевых каналов (КК) и проявляет нитратоподобные свойства. Цель данного обзора — представить современный взгляд на лечение никорандилом. Приводятся показания к применению никорандила, объясняется механизм его действия. Обсуждается феномен ишемического и фармакологического прекондиционирования, особое внимание уделяется роли КК. Рассматриваются аспекты клинической практики, связанные с прекондиционированием ишемии и ее медикаментозной профилактикой с помощью никорандила, а также влияние препарата на улучшение прогноза, оптимизацию функции эндотелия, регулирование работы вегетативной нервной системы и стабилизацию атеросклеротической бляшки. Обсуждается вопрос переносимости никорандила.

Об авторе

Ю. Б. Белоусов
ГБОУ ВПО Российский национальный исследовательский медицинский университет им. Н.И. Пирогова
Россия
кафедра госпитальной терапии № 2 лечебного факультета


Список литературы

1. Abdallah Y., Wolf C., Meuter K. et al. Preconditioning with diazoxide prevents reoxygenation-induced rigor-type hypercontracture // J. Mol. Cell Cardiol. 2010. Vol. 48 (I). P. 270–6.

2. Boden W.H., O’Rourke R.A., Tco K.K. et al. Optimal medical therapy with or without PCI for stable coronarv disease // N. Engl. J. Med. 2007. Vol. 356, № 15. Р. 1503–16.

3. Сlinical guideline 126: Management of stable angina. National Institute for Health and Clinical Excellence, UK. July 2011. P. 14–15.

4. Di Lisa F., Menabo R., Canton M. et al. Opening of the mitochondrial permeability transition pore causes depletion of mitochondrial and cytosolic NAD+ and is a causative event in the death of myocytes in postischemic reperfusion of the heart // J. Biol. Cheni. 2001. Vol. 276, № 4. Р. 2571–5.

5. Di Somma S., Liguori V., Petitto M. et al. A double-blind comparison of nicorandil and meloprolol in stable effort angina pectoris // Cardiovasc. Drugs Ther. 1993. Vol. 7 (I). P. 119–23.

6. Doring G. Antianginal and anti-ischemic efficacy of nicorandil in comparison with isosorbide-5-mononitrate and isosorbide dinitrate: results from two multicenter, double-blind, randomized studies with stable coronary heart disease patients // J. Cardiovasc. Pharmacol. 1992. Vol. 20, Suppl. 3. P. 74–81.

7. Dunn N., Freemautle S., Pearce G. et al. Safety profile of nicorandil: prescription-event monitoring (PEM) study // Pharmacoepidemiol. Drug. Saf. 1999. Vol. 8, № 3. Р. 197–205.

8. Eguchi Y., Takahari Y., Higashijima N. el al. Nicorandil attenuates FcCI(3)-induced thrombus formation through the inhibition of reactive oxygen species production // Circ. J. 2009. Vol. 73, № 3. Р. 554–61.

9. Frye R.I., August F., Brooks M.M. et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease // N. Engl. J. Med. 2009. Vol. 360, № 24. Р. 2503–15.

10. Guermonprez J.L,. Blin P., Peterlongo P. A double-blind comparison of the long-term efficacy of a potassium channel opener and a calcium antagonist in stable angina pectoris // Eur. Heart J. 1993. Vol. 14, Suppl. B. P. 30–4.

11. Hausenloy D.J. Signalling pathways in ischaemic postconditioning // Thromb. Haemost. 2009. Vol. 101, № 4. Р. 626–34.

12. Henderson R.A., Pocock S.J., Clayton T.C. et al. Seven-year outcome in the RITA-2 trial: coronary angioplasty versus medical therapy // J. Am. Coll. Cardiol. 2003. Vol. 42, № 7. Р. 1161–70.

13. Hirose M., Tsujino N., Nakada T. et al. Mechanisms of preventive effect of nicorandil on ischaemia-induced ventricular tachyarrhythmia in isolated arterially perfused canine left ventricular wedges // Basic Clin. Pharmacol. Toxicol. 2008. Vol. 102, № 6. Р. 504–14.

14. Hoehman J.S., Lamas G.A., Buller C.E. et al. Coronary intervention for persistent occlusion after myocardial infarction // N. Engl. J. Med. 2006. Vol. 355, № 23. Р. 2395–407.

15. Holzmann S. Cyclic GM Pas possible mediator of coronary arterial relaxation by nicorandil (SG-75) // J. Cardiovasc. Pharmacol. 1983. Vol. 5, № 3. Р. 364–70.

16. Holzmann S., Kukovetz W.R., Braida C. et al. Pharmacological interaction experiments differentiate between glibenclamide-sensitive K+ channels and cyclic GMP as components of vasodilation by nicorandil // Eur. J. Pharmacol. 1992. Vol. 215, № 1. Р. 1–7.

17. Hughes L.O., Rose E.L., Lahiri A. et al. Comparison of nicorandil and atenolol in stable angina pectoris // Am. J. Cardiol. 1990. Vol. 66, № 7. Р. 679–82.

18. IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial // Lancet. 2002. Vol. 359, № 9314. Р. 1269–75.

19. Ishibashi Y., Takahashi N., Tokumaru A. et al. Effects of long-term nicorandil administration on endothelial function. inflammation, and oxidative stress in patients without coronary artery disease // J. Cardiovasc. Pharmacol. 2008. Vol. 51, № 3. Р. 311–6.

20. Ishihara M., Sato H., Tateishi H. et al. Implications of prodromal angina pectoris in anterior wall acute myocardial infarction: acute angiographic findings and long-term prognosis // J. Am. Coll. Cardiol. 1997. Vol. 30, № 4. Р. 970–5.

21. Ishii H., Ichimiya S., Kanashiro M. et al. Impact of a single intravenous administration of nicorandil before reperfusion in patients with ST-segment-elevalion myocardial infarction // Circulation. 2005. Vol. 112, № 9. Р. 1284–8.

22. Izumiya Y., Kojima S., Kojima S. et al. Long-term use of oral nicorandil stabilizes coronary plaque in patients with stable angina pectoris // Atherosclerosis. 2011. Vol. 214, № 2. Р. 415–21.

23. Japanese Coronary Artery Disease (JCAD) Study Investigators. Current status of the background of patients with coronary artery disease in Japan // Circ. J. 2006. Vol. 70, № 10. Р. 1256–62.

24. Kang C.S., Chen C.C., Lin C.C. et al. Effect of ATP-sensitive potassium channel agonists on sympathetic hyperinnervation in postinfarcted rat hearts // Am. J. Physiol. Heart. Circ. Physiol. 2009. Vol. 296, № 6. Р. 1949–59.

25. Kasama S., Toyama T., Hatori T. et al. Comparative effects of nicorandil with isosorbide mononitrate on cardiac sympathetic nerve activity and left ventricular function in patients with ischemic cardiomyopathy // Am. Heart. J. 2005. Vol. 150, № 3. Р. 477–477.

26. Kasama S., Toyama T., Sumino H. et al. Long-term nicorandil therapy improves cardiac sympathetic nerve activity after reperfusion therapy in patients with first acute myocardial infarction // J. Nuel. Med. 2007. Vol. 48, № 10. Р. 1676–82.

27. Kishida H., Murao S. Effect of a new coronary vasodilator, nicorandil on variant angina pectoris // Clin. Pharmacol. Ther. 1987. Vol. 42, № 2. Р. 166–74.

28. Kitakaze M., Asakura M., Kim J. et al. Human atrial natriuretic peptide and nicorandil as adjunets to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials // Lancet. 2007. Vol. 370, № 9597. Р. 1483–93.

29. Kloner R.A., Shook T., Antman E.M. et al. Prospective temporal analysis of the onset of preinfarction angina versus outcome: an ancillary study in TIMI-9B // Circulation. 1998. Vol. 97, № 11. Р. 1042–5.

30. Kukovetz W.R., Holzmann S., Braida C. et al. Dual mechanism of the relaxing effect of nicorandil by stimulation of cyclic GMP formation and by hyperpolarization // J. Cardiovasc. Pharmacol. 1991. Vol. 17, № 4. Р. 627–33.

31. Kukovetz W.R., Holzmann S., Poch G. Molecular mechanism of action of nicorandil // J. Cardiovasc. Pharmacol. 1992. Vol. 20, Suppl. 3. P. 1–7.

32. Lablanche J.M., Bauters C., Leroy F. et al. Prevention of coronary spasm by nicorandil: comparison with nifedipine // J. Cardiovasc. Pharmacol. 1992. Vol. 20, Suppl. 3. P. 82–5.

33. Lablanche J.M., Banters C., McFadden E.P. et al. Potassium channel activators in vasospastic angina // Eur. Heart. J. 1993. Vol. 14, Suppl. B. P. 22–4.

34. Lai C., Onnis E., Solinas R. et al A new anti-ischemic drug for the treatment of stable effort angina pectoris: nicorandil: comparison with placebo and isosorbide-mononitrate (in Italian) // Cardiologia. 1991. Vol. 36, № 9. Р. 703–11.

35. Matsubara T., Minatoguchi S., Matsuo H. et al. Three minute, but not one minute, ischemia and nicorandil have a preconditioning effort in patients with coronary artery disease // J. Am. Coll. Cardiol. 2000. Vol. 35, № 2. Р. 345–51.

36. Matsuo H., Watanabe S., Segawa T. et al. Evidence of pharmacologic preconditioning during PTCA by in-travenous pretreatmcnt with ATP-sensitive K+ channel opener nicorandil // Eur. Heart J. 2003. Vol. 24, № 14. Р. 1296–303.

37. Meeter K., Kelder J.C., Tijssen J.G. et al. Efficacy of nicorandil versus propranolol in mild stable angina pectoris of effort: a long-term, double-blind, randomized study // J. Cardiovasc. Pharmacol. 1992. Vol. 20, Suppl. 3. P. 59–66.

38. Murry C.E., Jennings R.B., Reimer K.A. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium // Circulation. 1986. Vol. 74, № 5. Р. 1124–36.

39. Ozcan C., Terzic A., Bienengraeber M. Effective pharmacotherapy against oxidative injury: alternative utility of an ATP-sensitive potassium channel opener // J. Cardiovasc. Pharmacol. 2007. Vol. 50, № 4. Р. 411–8.

40. Piper H.M., Garena-Dorado D., Ovize M. A fresh look at reperfusion injury // Cardiovasc. Res. 1998. Vol. 38, № 2. Р. 291–300.

41. Roland F. Safety profile of an anti-anginal agent with potassium channel opening activity: an overview // Eur. Heart J. 1993. Vol. 14, Suppl. B. P. 48–52.

42. Sanada S., Node K., Asanuma H. et al. Opening of the adenosine triphosphate-sensitive potassium channel attenuates cardiac remodeling induced by long-term inhibition of nitric oxide synthesis: role of 70-kDa S6 kinase and extracellular signalregulated kinase // J. Am. Coll. Cardiol. 2002. Vol. 40, № 5. Р. 991–7.

43. Sasaki J., Saeki Y., Kawasaki K. et al. A multicenter comparison of nicorandil and diltiazem on serum lipid, apolipoprotein. and lipoprotein levels in patients with ischemic heart disease // Cardiovasc. Drugs. Ther. 1992. Vol. 6, № 51. Р. 471–4.

44. Sekiya M., Sato M., Funada J. et al. Effects of the long-term administration of nicorandil on vascular endothelial function and the progression of arteriosclerosis // J. Cardiovasc. Pharmacol. 2005. Vol. 46, № 11. Р. 63–7.

45. Simpson D., Wellington K. Nicorandil: a review of its use in the management of stable angina pectoris, including high-risk patients // Drugs. 2004. Vol. 64, № 17. Р. 1941–55

46. Solaim G., Harris D.A. Biochemical dysfunction in heart mitochondria exposed to ischaemia and reperfusion // Biochem. J. 2005. Vol. 390 (Pt. 2). P. 377–94.

47. Taira N. Nicorandil as a hybrid between nitrates and potassium channel activators // Am. J. Cardiol. 1989. Vol. 63, № 21. Р. 18–24.

48. Tanaka K., Kato K., Takano T. et al. Acute effects of intravenous nicorandil on hemodynamics in patients hospitalized with acute decompensated heart failure // J. Cardiol. 2010. Vol. 56, № 3. Р. 291–9.

49. The SWAN Study Group. Comparison of the antiischaemic and antianginal effects of nicorandil and amlodipine in patients with symptomatic stable angina pectoris: the SWAN study // J. Clin. Basic. Cardiol. 1999. № 2. Р. 213–7.

50. Tsutamoto T., Kinoshita M., Nakae I. et al. Absence of hemodynamic tolerance to nicorandil in patients with severe congestive heart failure // Am. Heart. J. 1994. Vol. 127 (4 Pt. I). P. 866–73.

51. Ueda H., Nakayama Y., Tsumura K. et al. Intravenous nicorandil can reduce the occurrence of ventricular fibrillation and QT dispersion in patients with successful coronary angioplasty in acute myocardial infarction // Can. J. Cardiol. 2004. Vol. 20, № 6. Р. 625–9.

52. Ulvenstam G., Diderholm E., Frithz G. et al. Antianginal and antiischaemic efficacy of nicorandil compared with nifedipine in patients with angina pectoris and coronary heart disease: a double-blind, randomized, multicenter study // J. Cardiovasc. Pharmacol. 1992. Vol. 20, Suppl. 3. P. 67–73.

53. Witchitz S., Darmon J.Y. Nicorandil safety in the long-term treatment of coronary heart disease // Cardiovasc. Drugs. Ther. 1995. Suppl. 2. P. 237–43.

54. Zhu W.L., Shan Y.D., Guo J.X. et al. Double-blind, multicenter. active-controlled, randomized clinical trial to assess the safety and efficacy of orally administered nicorandil in patients with stable angina pectoris in China // Cirv. J. 2007. Vol. 71, № 6. Р. 826–33.


Для цитирования:


Белоусов Ю.Б. ПРИМЕНЕНИЕ НИКОРАНДИЛА ПРИ СЕРДЕЧНО-СОСУДИСТЫХ ЗАБОЛЕВАНИЯХ И ОПТИМИЗАЦИЯ СХЕМ ЕГО НАЗНАЧЕНИЯ. Архивъ внутренней медицины. 2012;(1):46-52. https://doi.org/10.20514/2226-6704-2012-0-1-46-52

For citation:


Белоусов Ю.Б. ПРИМЕНЕНИЕ НИКОРАНДИЛА ПРИ СЕРДЕЧНО-СОСУДИСТЫХ ЗАБОЛЕВАНИЯХ И ОПТИМИЗАЦИЯ СХЕМ ЕГО НАЗНАЧЕНИЯ. The Russian Archives of Internal Medicine. 2012;(1):46-52. (In Russ.) https://doi.org/10.20514/2226-6704-2012-0-1-46-52

Просмотров: 199


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2226-6704 (Print)
ISSN 2411-6564 (Online)